cr at 12.5 reported by afr street talk

AFR

Blood test biotech Anteo Diagnostics, chaired by TV’s (and Yellow Brick Road’s) Mark Bouris, is seeking to raise as much as $7.5 million. Bell Potter is managing the deal.

The shares were being offered at 12.5¢ apiece. Anteo’s patented technology is Mix&Go, a “molecular glue” used in life sciences, pathology tests and point-of-care diagnostics to help identify and detect diseases more reliably and earlier.

Since 2009, Anteo, capitalised at $119 million, has secured commercial agreements with companies such as Bangs, Merck, One World Lab and BBI.

The shares were placed in a trading halt on Thursday morning.